Combination of mesenchymal stromal cells and machine perfusion is a novel strategy for organ preservation in solid organ transplantation

被引:0
作者
Lingfei Zhao
Chenxia Hu
Fei Han
Dajin Chen
Yanhong Ma
Fanghao Cai
Jianghua Chen
机构
[1] Zhejiang University,Kidney Disease Center, the First Affiliated Hospital, College of Medicine
[2] Zhejiang University,Key Laboratory of Kidney Disease Prevention and Control Technology
[3] Zhejiang University,Institute of Nephrology
[4] Zhejiang University,State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine
来源
Cell and Tissue Research | 2021年 / 384卷
关键词
Mesenchymal stromal cells; Machine perfusion; Organ preservation; Solid organ transplantation; Regenerative medicine;
D O I
暂无
中图分类号
学科分类号
摘要
Organ preservation is a prerequisite for an urgent increase in the availability of organs for solid organ transplantation (SOT). An increasing amount of expanded criteria donor (ECD) organs are used clinically. Currently, the paradigm of organ preservation is shifting from simple reduction of cellular metabolic activity to maximal simulation of an ex vivo physiological microenvironment. An ideal organ preservation technique should not only preserve isolated organs but also offer the possibility of rehabilitation and evaluation of organ function prior to transplantation. Based on the fact that mesenchymal stromal cells (MSCs) possess strong regeneration properties, the combination of MSCs with machine perfusion (MP) is expected to be superior to conventional preservation methods. In recent years, several studies have attempted to use this strategy for SOT showing promising outcomes. With better organ function during ex vivo preservation and the potential of utilization of organs previously deemed untransplantable, this strategy is meaningful for patients with organ failure to help overcome organ shortage in the field of SOT.
引用
收藏
页码:13 / 23
页数:10
相关论文
共 267 条
  • [1] Abecassis M(2008)Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference Clin J Am Soc Nephrol 3 471-480
  • [2] Bartlett ST(2012)Is extracorporeal hypothermic machine perfusion of the liver better than the 'good old icebox' Curr Opin Organ Transplant 17 137-142
  • [3] Collins AJ(2012)Therapeutic potential of mesenchymal stem cell-derived microvesicles Nephrol Dial Transplant 27 3037-3042
  • [4] Bae C(2012)New strategies to optimize kidney recovery and preservation in transplantation Nat Rev Nephrol 8 339-347
  • [5] Henry SD(2019)Potentiating renal regeneration using mesenchymal stem cells Transplantation 103 307-313
  • [6] Guarrera JV(2002)Overcoming severe renal ischemia: the role of ex vivo warm perfusion Transplantation 73 897-901
  • [7] Biancone L(2016)Role of TLRs and DAMPs in allograft inflammation and transplant outcomes Nat Rev Nephrol 12 281-290
  • [8] Bruno S(2012)Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by microRNA-dependent reprogramming of resident renal cells Kidney Int 82 412-427
  • [9] Deregibus MC(2020)Heme oxygenase-1-modified bone marrow mesenchymal stem cells combined with normothermic machine perfusion to protect donation after circulatory death liver grafts Stem Cell Res Ther 11 218-2360
  • [10] Tetta C(2015)AKI recovery induced by mesenchymal stromal cell-derived extracellular vesicles carrying MicroRNAs J Am Soc Nephrol 26 2349-776